Genolution

Genolution Asset Growth

The Year-over-Year Total Asset Growth of Genolution (225220.KQ) as of Oct 22, 2026 is -11.90 %. In the previous year, Year-over-Year Total Asset Growth was -6.16 % — a change of 93.23% (lower).

Asset Growth

-11.90 %

YoY

93.23%

Last updated:

Year-over-Year Total Asset Growth of Genolution is 2025 -11.90 % . Year-over-Year Total Asset Growth of Genolution was 2024 -6.16 % . It decreases by 93.23% lower compared to the previous year.

The Genolution Asset Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Asset Growth
Date
Asset Growth
Jan 1, 2018
135.83 KRW
Jan 1, 2019
21.01 KRW
Jan 1, 2020
523.86 KRW
Jan 1, 2021
13.33 KRW
Jan 1, 2022
20.55 KRW
Jan 1, 2023
-0.89 KRW
Jan 1, 2024
-6.16 KRW
Jan 1, 2025
-11.90 KRW
The Genolution Asset Growth history
YEARAsset GrowthYoY
-11.90 %+93.23%
-6.16 %+593.72%
-0.89 %-104.32%
20.55 %+54.17%
13.33 %-97.46%
523.86 %+2,393.14%
21.01 %-84.53%
135.83 %+663.79%
17.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Genolution Stock analysis

What does Genolution do? Genolution Inc develops automated nucleic acid extraction devices, nucleic acid extraction reagents, and molecular diagnostic products. The company also offers ribonucleic acid interference services. Its products are distributed domestically and internationally, serving customers in the biotechnology and healthcare sectors. The firm generates revenue through the sale of these products and services to research institutions, laboratories, and healthcare providers. The company's core offerings include nucleic acid extractors, reagents, and diagnostic products, which are used in molecular biology and medical diagnostics. Genolution Inc targets biotech firms, hospitals, and research facilities as key buyers of its technology. Its domestic market presence complements its international distribution channels. Genolution Inc's business model relies on selling its automated extraction devices and reagents to customers requiring efficient nucleic acid processing solutions. The company's molecular diagnostic products cater to healthcare applications, while its ribonucleic acid interference services support advanced research needs. Revenue streams are derived from both product sales and service contracts within the biotechnology industry. Genolution is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genolution stock

Year-over-Year Total Asset Growth of Genolution is -11.90 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Total Asset Growth Genolution since 2006 – with annual values, charts, and detailed analysis.

Asset growth measures the percentage change in total assets. Rapid asset growth may indicate expansion but can also correlate with lower future returns.

To evaluate Year-over-Year Total Asset Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Total Asset Growth.

Year-over-Year Total Asset Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Total Asset Growth's Genolution historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Genolution

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Genolution